Analysts Offer Predictions for Genmab A/S FY2026 Earnings

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Genmab to $1.46 from $1.51, still above the broader consensus estimate of $1.22. The firm maintained a Buy rating and a $70 price target.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $53.61, with recent targets ranging from $52 to $80.
• Genmab reported quarterly EPS of $0.56, beating the $0.36 consensus, though revenue of $1.19 billion fell slightly short of estimates.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright decreased their FY2026 earnings estimates for Genmab A/S in a research report issued on Friday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.46 per share for the year, down from their prior forecast of $1.51. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Genmab A/S's Q4 2026 earnings at $0.34 EPS, Q1 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.47 EPS and FY2027 earnings at $1.60 EPS.

A number of other research analysts also recently issued reports on the stock. Truist Financial restated a "buy" rating and set a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. Guggenheim increased their price target on Genmab A/S from $58.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. New Street Research set a $43.00 price objective on Genmab A/S in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, September 1st. Finally, TD Cowen lifted their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the company a "buy" rating in a report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average target price of $53.61.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $55.80 on Tuesday. The company has a 50 day simple moving average of $39.63 and a two-hundred day simple moving average of $31.22. The stock has a market cap of $34.82 billion, a price-to-earnings ratio of 39.65, a PEG ratio of 2.17 and a beta of 0.73. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.20. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. WINTON GROUP Ltd lifted its stake in Genmab A/S by 158.9% in the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company's stock valued at $1,124,000 after buying an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC purchased a new position in Genmab A/S during the first quarter worth approximately $1,216,000. SummitTX Capital L.P. purchased a new position in Genmab A/S during the first quarter worth approximately $2,263,000. Legacy Wealth Asset Management LLC boosted its stake in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company's stock worth $2,806,000 after buying an additional 63,484 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock worth $118,442,000 after buying an additional 921,700 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.